Active substance
Folinic acid
- SFDA 9
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CALCIUM FOLINATE 50MG-5ML VIAL | 10 mg/ml | Solution · Intravenous use | 1 Vial | SAR 82.15 | NCE · Prescription | HOSPIRA UK LIMITED | Valid |
| Calciumfolinat Sandoz 10MG-ML VIAL | 10 mg/ml | Solution for injection · Intravenous use | 1 Vial | SAR 53.80 | Generic · Prescription | Sandoz GmbH | Valid |
| Calciumfolinat Sandoz 10MG-ML VIAL | 10 mg/ml | Solution for injection · Intravenous use | 1 Vial | SAR 164.75 | Generic · Prescription | SANDOZ GMBH | Valid |
| CALCIUM FOLINATE (EBEWE) 10MG-ML AMP. | 10 mg/ml | Solution for injection/infusion · Intravenous use | 5 Ampoule | SAR 90.85 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
| CALCIUM FOLINATE (EBEWE) 10MG-ML AMP. | 10 mg/ml | Solution for injection/infusion · Intravenous use | 5 Ampoule | SAR 148.40 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
| CALCIUM FOLINATE (EBEWE) 10MG-ML AMP. | 10 mg/ml | Solution for injection/infusion · Intravenous use | 5 Ampoule | SAR 246.45 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
| CALCIUM FOLINATE (EBEWE)3MG-ML AMP. | 3 mg/ml | Solution · Intravenous use | 10 Ampoule | SAR 48.00 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
| CALCIUM LEUCOVORIN VIAL 50 MG POWDER | 50 mg | Injection · Parenteral use | 1 Vial | SAR 107.80 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| LEUCOVORIN CALCIUM 15MG-2ML VIAL | 7.5 mg/ml | Solution for injection · Intravenous use | 5 Vial | SAR 106.10 | NCE · Prescription | HOSPIRA AUSTRALIA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ADULT ACUTE LYMPHOCYTIC LEUKEMIA (ALL)-ADVERSE REACTIONS MANAGEMENT; BREAST CANCER EARLY HER-2 -VE -ADVERSE REACTION MANAGEMENT; BREAST CANCER MET.HER-2 -VE-ADVERSE REACTION MANAGEMENT; BURKITT`S LYMPHOMA; COLORECTAL CANCER-EARLY & ADVANCED; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; ESOPHAGEAL CANCER; GASTRIC CANCER; INFECTIOUS UVEITIS; JUVENILE IDIOPATHIC ARTHRITIS (JIA); MALIGNANT NEOPLASM OF THE PANCREAS; MANTLE CELL LYMPHOMA; MYASTHENIA GRAVIS; PEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)-ADVERSE REACTIONS MANAGEMENT; PEDIATRIC B-CELL LYMPHOMA; PSORIATIC ARTHRITIS; RHEUMATOID ARITHRITIS-SUPPORTIVE CARE AND ADRS MANAGEMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; T-CELL LYMPHOMA
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.